OMass Therapeutics, a UK BioTech company developing small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed €275 million (£230 million) Series C round. The round was co-led by…
Tag:
therapies
-
-
yuelan Johnson & Johnson (JNJ) announced on Wednesday a strategic deal with Sail Biomedicines to advance in vivo CAR-T therapies for immune-mediated diseases, along with an option to acquire Sail…
